Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells
Exploration · 2026-10 · 6 (5)
DOI: 10.1002/exp2.70239 ↗At a glance
Übersichtsarbeit in Exploration, published online on 2026-10-11. Written by Hao Li and 7 co-authors. Institution: Department of Medical Oncology the First Affiliated Hospital of Soochow University Suzhou China. 184 references. The full text is freely available (open access, CC BY 4.0). Funded by: China Postdoctoral Science Foundation, National Natural Science Foundation of China.
Abstract (original language)
Circulating tumor cells (CTCs), as pivotal targets in liquid biopsy, offer dynamic, multidimensional insights into tumor heterogeneity and metastatic progression. However, their extreme rarity, pronounced heterogeneity, and the complexity of the blood microenvironment severely constrain detection accuracy. Advances in micro/nanomaterials and functional device engineering have enabled substantial improvements in CTC enrichment efficiency by refining the topographical and chemical properties of capture interfaces. These innovations also provide a compatible foundation for multimodal molecular profiling. This review systematically outlines the structure–function relationships of functionalized nanomaterials, microfiltration substrates, and biomimetic microfluidic devices, highlighting how material parameters—such as nanoscale architectures and membrane pore sizes—govern CTC capture performance. We further explore the integration of micro/nanomaterials with functional platforms for multidimensional molecular analyses across DNA, RNA, and protein levels. Coupled with emerging digital PCR technologies, these systems show promise in overcoming the sensitivity barriers associated with rare mutation detection and protein quantification, enabling multi‐omics data fusion. We also discuss how artificial intelligence (AI)‐driven feature selection, clustering, and prediction integrate multidimensional data to decode tumor heterogeneity and guide disease monitoring. Despite rapid progress, key challenges remain—including the lack of standardization, limited integration of multi‐omic datasets, and the need for robust clinical validation. Future directions may lie in the convergence of microfluidic‐integrated materials, single‐cell multi‐omics, and AI‐driven analytics to establish dynamic, high‐resolution monitoring platforms that bridge the gap between fundamental research and clinical precision oncology.
Subjects
Author keywords
Authors and institutions
- Department of Medical Oncology the First Affiliated Hospital of Soochow University Suzhou China.
- Suzhou Institute of Biomedical Engineering and Technology Chinese Academy of Sciences Suzhou China.
- State Key Laboratory on Technologies for Chinese Medicine Pharmaceutical Process Control and Intelligent Manufacture Nanjing University of Chinese Medicine Nanjing China.
- School of Electrical and Electronic Engineering Nanyang Technological University Singapore Singapore.
Funding
- China Postdoctoral Science Foundation
- National Natural Science Foundation of China
Cite
APA
Li, H., Sun, J., Liu, K., Wang, S., Fu, B., Zhu, H., Cao, P., & Han, X. (2026). Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells. Exploration, 6(5). https://doi.org/10.1002/exp2.70239
Vancouver
Li H, Sun J, Liu K, Wang S, Fu B, Zhu H, et al. Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells. Exploration. 2026;6(5). doi:10.1002/exp2.70239
BibTeX
@article{Li2026,
author = {Li, Hao and Sun, Jiaojiao and Liu, Kunguo and Wang, Shijie and Fu, Bowen and Zhu, Hong and Cao, Peng and Han, Xin},
title = {Micro/Nanostructured Materials and Microfluidic Diagnostic Platforms Enable Multimodal Detection of Circulating Tumor Cells},
journal = {Exploration},
year = {2026},
volume = {6},
number = {5},
doi = {10.1002/exp2.70239}
}
EUVIMED